<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1808245774
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        EZORA 20 MG GASTRO-RESISTANT HARD CAPSULES (28S)
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ESOMEPRAZOLE SODIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Gastro-resistant capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        52.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="TOWA PHARMACEUTICAL EUROPE S L" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            TOWA PHARMACEUTICAL EUROPE S L
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A02BC05 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>EZORA contains a medicine called esomeprazole, which belongs to a group of medicines called &rsquo;proton pump inhibitors&rsquo;. They work by reducing the amount of acid that your stomach produces.</p><p>EZORA is used to treat the following conditions:</p><p>Adults</p><p>- &lsquo;Gastro-esophageal reflux disease&rsquo; (GERD). This is where acid from the stomach escapes into the gullet (the tube which connects your throat to your stomach) causing pain, inflammation and heartburn.</p><p>- Ulcers in the stomach or upper part of the gut (intestine) that are infected with bacteria called &lsquo;Helicobacter pylori&rsquo;. If you have this condition, your doctor may also prescribe antibiotics to treat the infection and allow the ulcer to heal.</p><p>- Stomach ulcers caused by medicines called NSAIDs (Non-Steroidal AntiInflammatory Drugs). EZORA can also be used to stop stomach ulcers from forming if you are taking NSAIDs.</p><p>- Too much acid in the stomach caused by a growth in the pancreas (Zollinger-Ellison syndrome).</p><p>- Prolonged treatment after prevention of re-bleeding of ulcers with intravenous esomeprazole.</p><p>Adolescents aged 12 years and above</p><p>&lsquo;Gastro-esophageal reflux disease&rsquo; (GERD). This is where acid from the stomach escapes into the gullet (the tube which connects your throat to your stomach) causing pain, inflammation and heartburn.</p><p>- Ulcers in the stomach or upper part of the gut (intestine) that are infected with bacteria called &lsquo;Helicobacter pylori&rsquo;. If you have this condition, your doctor may also prescribe antibiotics to treat the infection and allow the ulcer to heal.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take EZORA</strong></p><p>- if you are allergic to esomeprazole or any of the other ingredients of this medicine (listed in section 6).</p><p>- if you are allergic to other proton pump inhibitor medicines (e.g. pantoprazole, lansoprazole, rabeprazole, omeprazole).</p><p>- if you are taking a medicine containing nelfinavir (used to treat HIV). Do not take EZORA if any of the above applies to you. If you are not sure, talk to your doctor or pharmacist before taking EZORA.</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor or pharmacist before taking EZORA:</p><p>- if you have severe liver problems.</p><p>- if you have severe kidney problems.</p><p>- if you have ever had a skin reaction after treatment with a medicine similar to EZORA that reduces stomach acid.</p><p>- If you are due to have a specific blood test (Chromogranin A).</p><p>EZORA may hide the symptoms of other diseases. Therefore, if any of the following happen to you before you start taking EZORA or while you are taking it, talk to your doctor straight away:</p><p>- you lose a lot of weight for no reason and have problems swallowing.</p><p>- you get stomach pain or indigestion.</p><p>- you begin to vomit food or blood.</p><p>- you pass black stools (blood-stained faeces).</p><p>If you have been prescribed EZORA &ldquo;on demand&rdquo; you should contact your doctor if your symptoms continue or change in character. Taking a proton pump inhibitor like EZORA, especially over a period of more than one year, may slightly increase your risk of fracture in the hip, wrist or spine. Tell your doctor if you have osteoporosis or if you are taking corticosteroids (which can increase the risk of osteoporosis). If you get a rash on your skin, especially in areas exposed to the sun tell your doctor as soon as you can, as you may need to stop your treatment with EZORA. Remember to also mention any other ill-effects like pain in your joints.</p><p><u>Children under the age of 12 years</u></p><p>Information on dosing for children aged 1 to 11 years is provided in esomeprazole sachet product information (ask your doctor or pharmacist if you require further information).<strong> </strong></p><p><strong>Other medicines and EZORA</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines that you buy without a prescription. This is because EZORA can affect the way some medicines work and some medicines can have an effect on EZORA. Do not take EZORA if you are taking a medicine containing nelfinavir (used to treat HIV infection). Tell your doctor or pharmacist if you are taking any of the following medicines:</p><p>- Atazanavir or saquinavir (used to treat HIVinfection).</p><p>- Clopidogrel (used to treat or prevent blood clots).</p><p>- Ketoconazole, itraconazole or voriconazole (used to treat infections caused by a fungus).</p><p>- Erlotinib (used to treat cancer).</p><p>- Citalopram, imipramine or clomipramine (used to treat depression).</p><p>- Diazepam (used to treat anxiety, relax muscles or in epilepsy).</p><p>- Phenytoin (used in epilepsy). If you are taking phenytoin, your doctor will need to monitor you when you start or stop taking EZORA.</p><p>- Medicines that are used to thin your blood, such as warfarin. Your doctor may need to monitor you when you start or stop taking EZORA.</p><p>- Cilostazol (used to treat intermittent claudication &ndash; a pain in your legs when you walk which is caused by an insufficient blood supply). - Cisapride (used for indigestion and heartburn).</p><p>- Digoxin (used for heart problems).</p><p>- Methotrexate (a chemotherapy medicine used in high doses to treat cancer) &nbsp;&ndash; if you are taking a high dose of methotrexate, your doctor may temporarily stop your EZORA treatment.</p><p>- Tacrolimus (organ transplantation).</p><p>- Rifampicin (used for treatment of tuberculosis).</p><p>- St. John&rsquo;s wort (Hypericumperforatum) (used to treat depression).</p><p>If your doctor has prescribed the antibiotics amoxicillin and clarithromycin as well as EZORA to treat ulcers caused by Helicobacter pylori infection, it is very important that you tell your doctor about any other medicines you are taking.</p><p><strong>EZORA with food and drink</strong></p><p>You can take your capsules with food or on an empty stomach.<strong> </strong></p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.Your doctor will decide whether you can take EZORA during this time. It is not known if EZORA passes into breast milk. Therefore, you should not take EZORA if you are breast-feeding.&nbsp;</p><p><strong>Driving and using machines :</strong></p><p>EZORA is not likely to affect your ability to drive or use any tools or machines.However, side effects such as dizziness and blurred vision may uncommonly or rarely occur (see section 4). If affected, you should not drive or use machines.</p><p><strong>EZORA contains sucrose :&nbsp;</strong></p><p>EZORA containssugar spheres which containsucrose, a type of sugar. If you have been told by your doctor that you have an intolerance to some sugars, talk to your doctor before taking this medicine.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. - If you are taking this medicine for a long time, your doctor will want to monitor you (particularly if you are taking it for more than a year). - If your doctor has told you to take this medicine as and when you need it, tell your doctor if your symptoms change.</p><p><strong>How much to take</strong></p><p>- Your doctor will tell you how many capsules to take and how long to take them for. This will depend on your condition and how well your liver works.</p><p>- The usual doses are given below.</p><p><u><strong>Use in adults aged 18 and above </strong></u></p><p><strong>To treat heartburn caused by gastro-oesophageal reflux disease (GERD): </strong></p><p>- If your doctor has found that your food pipe (gullet) has been slightly damaged, the usual dose is one capsule of EZORA 40 mg once a day for 4 weeks. Your doctor may tell you to take the same dose for a further 4 weeks if your gullet has not yet healed.</p><p>- The recommended dose once the gullet has healed is one capsule of EZORA 20 mg once a day.</p><p>- If your gullet has not been damaged, the usual dose is one capsule EZORA 20 mg each day. Once the condition has been controlled, your doctor may tell you to take your medicine as and when you need it, up to a maximum of one capsule of EZORA 20 mg each day.</p><p>- If you have severe liver problems, your doctor may give you a lower dose.</p><p><strong>To treat ulcers caused by Helicobacter pylori infection and to stop them coming back:</strong></p><p><strong>-</strong> The recommended dose is one capsule of EZORA 20 mg twice a day for one week.</p><p>- Your doctor will also tell you to take antibiotics called amoxicillin and clarithromycin.</p><p><strong>To treat stomach ulcers caused by NSAIDs (Non-Steroidal Anti-Inflammatory Drugs): </strong></p><p>- The recommended dose is one capsule of EZORA 20 mg once a day for 4 to 8 weeks.&nbsp;</p><p><strong>To prevent stomach ulcers if you are taking NSAIDs (Non-Steroidal Anti-Inflammatory Drugs): </strong></p><p><strong>-</strong> Therecommended dose is one capsule of EZORA 20 mg once a day.</p><p><strong>To treat too much acid in the stomach caused by a growth in the pancreas (ZollingerEllison syndrome): </strong></p><p><strong>-</strong>The recommended dose is one capsule of EZORA 40 mg twice a day.</p><p>- Your doctor will adjust the dose depending on your needs and will also decide how long you need to take the medicine for. The maximum dose is 80 mg twice a day.</p><p><strong>Prolonged treatment after prevention of re-bleeding of ulcers with intravenous esomeprazole: </strong></p><p>- The recommended dose is one capsule of EZORA 40 mg once a day for 4 weeks.</p><p>&nbsp;</p><p><u><strong>Use in adolescents aged 12 or above</strong></u></p><p><strong>To treat heartburn caused by gastroesophageal reflux disease (GERD): </strong></p><p>- If your doctor has found that your food pipe (gullet) has been slightly damaged, therecommended dose is one EZORA 40 mg gastro-resistant capsule once a day for 4 weeks. Your doctor may tell you to take the same dose for a further 4 weeks if your gullet has not yet healed.</p><p>- The recommended dose once the gullet has healed is one EZORA 20 mg gastro-resistant capsule once a day.</p><p>- If your gullet has not been damaged, the recommended dose is one EZORA 20 mg gastroresistant capsule each day.</p><p>- If you have severe liver problems, your doctor may give you a lower dose.</p><p><strong>To treat ulcers caused by Helicobacter pylori infection and to stop them coming back: </strong></p><p>- The recommended dose is one EZORA 20 mg gastro-resistant capsule twice a day for oneweek.</p><p>- Your doctor will also tell you to take antibiotics for example amoxicillin andclarithromycin.</p><p><strong>Taking this medicine</strong></p><p>- You can take your capsules at any time of the day.</p><p>- You can take your capsules with food or on an empty stomach.</p><p>- Swallow your capsules whole with a glass of water. Do not chew or crush the capsules or their contents. This is because the capsules contain coated granules which stop the medicine from being broken down by the acid in your stomach. It is important not to damage the granules.</p><p><strong>What to do if you have trouble swallowing the capsules </strong></p><p>- If you have trouble swallowing the capsules:</p><p>1. Open the capsule carefully above a glass of still (non-fizzy) water and empty the content of the capsule (granules) into the glass. Do not use any other liquids.&nbsp;</p><p>2. Stir. Then drink the mixture straight away or within 30 minutes. Always stir the mixture just before drinking it.</p><p>3. To make sure that you have drunk all of the medicine, rinse the glass very well with half a glass of water and drink it. The solid pieces contain the medicine - do not chew or crush them.</p><p>- If you cannot swallow at all, the content of the capsule can be mixed with some water and put into a syringe. It can then be given to you through a tube directly into your stomach (&lsquo;gastric tube&rsquo;).</p><p><strong>Use in children under the age of 12 years </strong></p><p>EZORA gastro-resistant capsules are not recommended for children less than 12 years old. Information on dosing for children aged 1 to 11 years is provided in esomeorazole sachet product information (ask your doctor or pharmacist if you require further information).<strong> </strong></p><p><strong>Elderly</strong></p><p>Dose adjustment is not required in the elderly.</p><p>I<strong>f you take more EZORA than you should</strong></p><p>If you take more EZORA than prescribed by your doctor, Talk to your doctor or pharmacist straight away.<strong> </strong></p><p><strong>If you forget to take EZORA</strong></p><p>- If you forget to take a dose, take it as soon as you remember it. However, if it is almost time for your next dose, skip the missed dose. - Do not take a double dose (two doses at the same time) to make up for a forgotten dose. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>If you notice any of the following serious side effects, stop taking EZORA and contact a doctor immediately: </strong></p><p>- Sudden wheezing, swelling of your lips, tongue and throat or body, rash, fainting or difficulties to swallow (severe allergic reaction).</p><p>- Reddening of the skin with blisters or peeling. There may also be severe blisters and bleeding in the lips, eyes, mouth, nose and genitals. This could be &lsquo;Stevens-Johnson syndrome&rsquo; or &lsquo;toxic epidermal necrolysis&rsquo;.</p><p>- Yellow skin, dark urine and tiredness which can be symptoms of liver problems. These effects are rare, may affect up to 1 in 1,000 people.</p><p>&nbsp;</p><p>Other side effects include:</p><p><strong>Common (may affect up to 1 to 10 people):</strong></p><p>- Headache.&nbsp;</p><p>- Effects on your stomach or gut: diarrhoea, stomach pain, constipation, wind (flatulence).</p><p>- Feeling sick (nausea) or being sick (vomiting).</p><p>- Benign polyps in the stomach.</p><p>&nbsp;</p><p><strong>Uncommon (may affect up to 1 in 100 people): </strong></p><p>- Swelling of the feet and ankles.</p><p>- Disturbed sleep (insomnia).</p><p>- Dizziness, tingling feelings such as &ldquo;pins and needles&rdquo;, feeling sleepy.</p><p>- Spinning feeling (vertigo).</p><p>- Dry mouth.</p><p>- Changes in blood tests that check how the liver is working.</p><p>- Skin rash, lumpy rash (hives) and itchy skin.</p><p>- Fracture of the hip, wrist or spine(if EZORA is used in high doses and over long duration).</p><p><strong>Rare (may affect up to 1 in 1,000 people):</strong></p><p><strong>-</strong> Blood problems such as a reduced number of white cells or platelets. This can cause weakness, bruising or make infections more likely.</p><p>- Low levels of sodium in the blood. This may cause weakness, being sick (vomiting) and cramps</p><p>. - Feeling agitated, confused or depressed.</p><p>- Taste changes.</p><p>- Eyesight problems such as blurred vision.</p><p>- Suddenly feeling wheezy or short of breath (bronchospasm).</p><p>- An inflammation of the inside of the mouth.</p><p>- An infection called &ldquo;thrush&rdquo; which can affect the gut and is caused by a fungus.</p><p>- Liver problems, including jaundice which can cause yellow skin, dark urine, and tiredness.</p><p>- Hair loss (alopecia).</p><p>- Skin rash on exposure to sunshine.</p><p>- Joint pains (arthralgia) or muscle pains (myalgia).</p><p>&nbsp;- Generally feeling unwell and lacking energy</p><p>- Increased sweating</p><p><strong>Very rare (may affect up to 1 in 10,000 people): </strong></p><p>- Changes in blood count including agranulocytosis (lack of white blood cells).</p><p>- Aggression.</p><p>- Seeing, feeling or hearing things that are not there (hallucinations).</p><p>- Severe liver problems leading to liver failure and inflammation of the brain.</p><p>- Sudden onset of a severe rash or blistering or peeling skin. This may be associated with a high fever and joint pains (Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis).</p><p>- Muscle weakness.</p><p>- Severe kidney problems.</p><p>- Enlarged breasts in men.&nbsp;</p><p><strong>Not known (frequency cannot be estimated from the available data):</strong></p><p>- If you are on EZORA for more than three months it is possible that the levels of magnesium in your blood may fall. Low levels of magnesium can be seen as fatigue, involuntary muscle contractions, disorientation, convulsions, dizziness, increased heart&nbsp;</p><p>rate. If you get any of these symptoms, please tell your doctor promptly. Low levels of magnesium can also lead to a reduction in potassium or calcium levels in the blood. Your doctor may decide to perform regular blood tests to monitor your levels of magnesium.</p><p>- Inflammation in the gut (leading to diarrhoea).</p><p>- Rash, possibly with pain in the joints</p><p>EZORA may in very rare cases affect the white blood cells leading to immune deficiency. If you have an infection with symptoms such as fever with a severely reduced general condition or fever with symptoms of a local infection such as pain in the neck, throat or mouth or difficulties in urinating, you must consult your doctor as soon as possible so that a lack of white blood cells (agranulocytosis) can be ruled out by a blood test. It is important for you to give information about your medication at this time.&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>Ifyougetanysideeffects, talk to your doctor, pharmacistor nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via The National Pharmacovigilance and Drug Safety Centre (NPC). By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- Keep out of the reach and sight of children.</p><p>- Do not use this medicine after the expiry date which is stated on the carton or blister foil. The expiry date refers to the last day of that month.</p><p>- Do not store above 30 &deg;C. Store in the original package in order to protect from moisture.</p><p>- Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substance is esomeprazole.</p><p>EZORA capsules come in two strengths containing 20 mg or 40 mg of esomeprazole (as sodium salt).</p><p>- The other ingredients are:</p><p><u>Capsule content:</u></p><p>Sugar spheres (containing maize starch and sucrose), methyl cellulose, talc, titanium dioxide (E-171), glycerol monostearate, polysorbate-80, methacrylic acid-ethyl acrylate copolymer (1:1) dispersion 30% (containing sodium lauryl sulphate, polysorbate-80 and methacrylic acid-ethyl acrylate copolymer), triethyl citrate and 20% emulsion of glycerol monostearate, triethyl citrate and polysorbate-80</p><p><u>Capsule shell:</u></p><p>Carrageenan, potassium chloride, red iron oxide (E-172), titanium tioxide (E-171), hypromellose, printing ink (containing Shellac, potassium hydroxide and black iron oxide (E172)).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                - EZORA 20 mg hard capsules have opaque pink cap and body, size 4, printed, 
containing spherical pellets.
- EZORA 40 mg hard capsules have opaque pink cap and body, size 2, printed, 
containing spherical pellets.
EZORA 20 mg is available in:
Aluminium/Aluminium blisters:
14 and 28 capsules.
EZORA 40 mg is available in:
Aluminium/Aluminium blisters:
14 and 28 capsules
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Manufactured by :</p><p>Towa Pharmaceutical Europe S.L.</p><p>C/ de Sant Mart&iacute;, 75-97,</p><p>Martorelles, 08107 Barcelona, Spain</p><p>For:</p><p>SPIMACO</p><p>Al-Qassim pharmaceutical plant</p><p>Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                February 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>تحتوى كبسولات إيزورا على مادة دوائية تسمى إيزوميبرازول. والتى تنتمى إلى مجموعة من الأدوية تسمى &quot;مثبطات مضخة البروتون&quot;. وهي تعمل عن طريق تقليل كمية الحمض الذي تفرزه المعدة.</p><p><strong>تستخدم كبسولات إيزورا فى علاج الحالات الآتية:</strong></p><p>فى حالة البالغين - مرض الارتجاع المعدى المريئى. حيث یتسلل الحمض من المعدة إلى المرئ (وهو الأنبوبة التى تربط ما بين الحلق والمعدة) مسببا ألم والتهاب وحرقة في المعدة . تقرحات فى المعدة والجزء العلوي من القناة الهضمية (الاثني عشر) والتى تنتج من الإصابة ببكتيريا تسمى هيليكوباكتر بيلورى. إذا أصبت بهه الحالة، قد يلجأ طبيبك المعالج إلى وصف مضادات حيوية لعلاج هذه العدوى ومساعدة تلك التقرحات على الالتئام.</p><p>- تقرحات المعدة والتى تسببها بعض الأدوية مثل مضادات الالتهاب غير الاستيرويدية. إيزورا قد يستخدم أيضا للحد من تكون تقرحات المعدة الناتجة عن استخدام مضادات الالتهاب غير الاستيرويدية.</p><p>- زيادة إفراز الحمض فى المعدة بسبب نمو فى البنكرياس (وهى ظاهرة تسمى زولينجر- إليسون).</p><p>- العلاج لفترات طويلة بعد منع عودة النزيف من القرحة بإستخدام حقن إيزوميبرازول الوريدية.</p><p>في حالة المراهقين من عمر 12 سنة وما أكبر</p><p>- مرض الارتجاع المعدى المريئى. حيث يتسلل الحمض من المعدة إلى المرئ (وهو الأنبوبة التى تربط ما بين الحلق والمعدة) مسببا ألم والتهاب وحرقة في المعدة.</p><p>- تقرحات فى المعدة والجزء العلوي من القناة الهضمية (الاثني عشر) والتى تنتج من الإصابة ببكتيريا تسمى هيليكوباكتر بيلوري</p><p>إذا أصبت بهذه الحالة، قديلجأ طبيبك المعالج إلى وصف مضادات حيوية لعلاج ھذه العدوى ومساعدة تلك التقرحات على الالتئام.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تقم بتناول كبسولات إيزورا فى الحالات الآتية:</p><p>- إذا كنت مصابا بفرط الحساسية تجاه مادة إيوميبرازول أو أى من المكونات الأخرى لهذا الدواء (والمذكورة فى القسم 6)</p><p>- إذا كنت مصابا بفرط الحساسية تجاه دواء آخر من مجموعة مثبطات مضخة البروتون (مثل: بانتوبرازول، لانزوبرازول، رابيبرازول، أوميبرازول).</p><p>- إذا كنت تستخدم أدوية تحتوى على نيلفينافير (وهو لعلاج فيروس نقص المناعة البشرية).</p><p>لا تقم بتناول كبسولات إيزورا فى حالة انطباق أى من الحالات المذكورة أعلاه عليك. إذا كنت غير واثق، تواصل مع طبيبك المعالج أو الصيدلى قبل البدء فى تناول كبسولات إيزورا.</p><p>ا<strong>لتحذيرات والاحتياطات:</strong></p><p>تواصل مع طبيبك المعالج أو الصيدلى قبل البدء فى تناول كبسولات إيزورا فى الحالات الآتية:</p><p>- إذا كانت لديك مشاكل حادة بالكبد.</p><p>- إذا كانت لديك مشاكل حادة بالكلى.</p><p>- إذا ظهر عليك في أي وقت مضى رد فعل تحسسي على&nbsp;الجلد بعد العلاج باستخدام دواء مماثل لإيزورا يعمل علي التقليل من حمض المعدة.</p><p>- إذا كان من المقرر إجراء اختبار دم محدد (كروموجرانين أ).</p><p>قديقوم إيزورا بإخفاء أعراض بعض الأمراض الأخرى.<strong> لذلك، فى حالة تعرضك لأى مما يلى قبل البدء فى تناول كبسولات إيزورا أو أثناء استخدامه ، تواصل مع طبيبك المعالج فى الحال</strong>:</p><p>- إذا تعرضت لنقص شديد غير مبرر فى الوزن ومشاكل فى البلع</p><p>.- إذا تعرضت لألم بالمعدة أو عسر هضم.</p><p>- إذا بدأت فى تقيؤ الطعام أو الدم.</p><p>- إذا كان البراز لديك لونه أسود (براز ملطخا بالدم).</p><p>&nbsp;</p><p>إذا تم وصف إيزورا لك &quot;حسب الحاجة&quot; فيجب عليك التواصل مع طبيبك المعالج فى حالة استمرار الأعراض أو تغير صفات تلك الأعراض. تناول مثبطات مضخة البروتون مثل إيزورا، وخاصة على مدار فترة تزيد عن سنة واحدة، قد يزيد قليلا من خطر الإصابة بكسور في عظام الفخذ، الرسغ أو العمود الفقري. أخبر طبيبك إذا كان لديك مرض هشاشة العظام أو إذا كنت تتناول الستيرويدات (التي يمكن أن تزيد من خطرهشاشة العظام).</p><p>اذا ظهر عليك طفح جلدي، وخاصة في المناطق المعرضة لأشعة الشمس أخبر طبيبك بأسرع ما يمكن، لأنك من الممكن أن تحتاج إلى التوقف عن العلاج باستخدام إيزورا. تذكر أيضا أن تقوم بذكر أي أعراض جانبية أخرى مثل ألام المفاصل.</p><p><u>الأطفال أصغر من 12 سنة</u></p><p>المعلومات الخاصة بجرعات الأطفال الذين تتراوح أعمارهم بين 1 إلى 11 سنة متاحة في معلومات منتج إيزوميبرازول أكياس (اسأل طبيبك أو الصيدلي إذا كنت بحاجة إلى مزيد من المعلومات).&nbsp;</p><p>ايزورا والأدوية الأخرى</p><p>أخبر طبيبك المعالج إذا كنت تتناول أو قد تناولت مؤخرا أى أدوية أخرى. وتتضمن الأدوية التي تم شراؤها دون وصفة طبية. وذلك بسبب أنه قد يؤثر إيزورا على طريقة عمل بعض الأدوية الأخرى وقد يتأثر أيضا ببعض الأدوية.</p><p>لا تقم بتناول إيزورا إذا كنت تستخدم دواء يحتوى على نيلفينافير (وهو لعلاج عدوي فيروس نقص المناعة البشرية). أخبر طبيبك المعالج إذا كنت تستخدم أيا من الأدوية الآتية:</p><p>- أتازانافير أو ساكوينافير (وهو لعلاج عدوي فيروس نقص المناعة البشرية).</p><p>- كلوبيدوجريل (الذي يستخدم في علاج أو منع تجلط الدم).</p><p>- كيتوكونازول أو إتراكونازول أو فوريكونازول (وهى أدوية لعلاج العدوى التى تسببها الفطريات).</p><p>- إيرلوتينيب (يستخدم لعلاج السرطان).</p><p>- سيتالوبرام أو إيميبرامين أو كلوميبرامين (لعلاج الاكتئاب).</p><p>- ديازيبام (وهو يستخدم لعلاج القلق وباسط للعضلات أو لعلاج الصرع).</p><p>- فينيتوين (لعلاج الصرع). إذا كنت تتناول فينيتوين، فسوف يحتاج طبيبك المعالج إلى ضبط الجرعة عند البدء فى تناول إيزورا أو عند التوقف عن تناول إيزورا.</p><p>- الأدوية التى تستخدم لخفض لزوجة الدم، مثل الوارفارين. فقد يحتاج طبيبك المعالج إلى ضبط الجرعة الخاصة بك عندما تبدأ أو تتوقف عن تناول كبسولات إيزورا.</p><p>- سيلوستازول (الذي يستخدم لعلاج العرج المتقطع-&nbsp;&nbsp;ألم في الساقين عند المشي والذي كان سببه إمدادات الدم غير الكافية).</p><p>- سيسابرايد (يستخدم لعلاج عسر الهضم وحرقة المعدة).</p><p>- ديجوكسين (الذي يستخدم في علاج مشاكل في القلب).</p><p>- ميثوتريكسات (دواء علاج كيميائي يستخدم بجرعات عالية لعلاج السرطان) - إذا كنت تتناول جرعة عالية من الميثوتريكسات، فإن طبيبك قد ينصحك بالتوقف مؤقتا عن العلاج باستخدام إيزورا.</p><p>- تاكروليمس (يستخدم في حالات زرع الأعضاء).</p><p>- ريفامبيسين (الذي يستخدم لعلاج السل).</p><p>- نبتة القديس جونز (هايبريكم بيرفوراتوم) (التي تستخدم لعلاج الاكتئاب).</p><p>فى حالة قيام طبيبك المعالج بوصف مضادات حيوية مثل أموكسيسيللين وكلاريثروميسين مع إيزورا لعلاج التقرحات الناتجة عن الإصابة ببكتيرياهيليكوباكتر بيلورى، فمن الضرورى إخبار طبيبك المعالج بشأن أى أدوية أخرى تتناولها.&nbsp;</p><p><strong>تناول إيزورا مع الطعام والشراب</strong></p><p>يمكنك تناول كبسولات إيزورا مع الطعام أو على معدة خالية.</p><p><strong>الحمل والرضاعة</strong></p><p>إذا كنتى حاملا أو تظنين أنك ربما تكونى حاملا أو تخططين لإنجاب طفل، إستشيري طبيبك المعالج قبل البدء فى تناول هذا الدواء. سوف يقرر طبيبك إذا كان من الممكن تناول إيزورا في هذه الفترة. لا توجد معلومات بشأن إفراز إيزورا فى لبن الأم. لذلك، يجب عليك عدم تناول إيزورا فى حالة قيامك بإرضاع طفلك طبيعيا.</p><p>ا<strong>لقيادة واستخدام الآلات</strong></p><p>ليس من المحتمل أن يؤثر إيزورا على قدرتك على القيادة أو استخدام الأدوات أو الآلات. ومع ذلك ، قد تظهر أعراضا جانبية مثل الدوخة وعدم وضوح الرؤية غير الشائعة أو نادرة الحدوث (انظر الفقرة 4 ) إذا تأثرت، يجب ألا تقود السيارة أو تستخدم الآلات.</p><p><strong>يحتوي إيزورا علي سكروز</strong></p><p>يحتوي إيزورا علي كريات سكرية تحتوي علي السكروز، وهو نوع من انواع السكر. إذ ا أخبرك الطبيب من قبل أن لديك حساسية مفرطة لبعض السكريات، تواصل مع طبيبك قبل تناول&nbsp;هذا الدواء.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>قم دائما بتناول هذا الدواء تماما كما أخبرك طبيبك المعالج. وفى حالة عدم تأكدك، تحقق من خلال التواصل مع طبيبك المعالج أو الصيدلى.</p><p>- فى حالة تناولك لهذا الدواء لفترة طويلة، فسوف يرغب طبيبك المعالج بإجراء فحص خاص بك (خصوصا فى حالة تناولك لهذا الدواء لأكثر من سنة).</p><p>- إذا أخبرك طبيبك المعالج بتناول هذا الدواء عند الحاجة، أخبر طبيبك المعالج فى حالة حدوث تغير فى الأعراض لديك.</p><p><strong>الجرعة</strong></p><p>- سوف يخبرك طبيبك المعالج بعدد الكبسولات التى يجب أن تتناولها والفترة الزمنية للعلاج. وسوف يعتمد ذلك على حالتك وعلى عمرك وعلى مدى كفاءة عمل الكبد لديك.</p><p>- الجرعات المعتادة مدونة أدناه.</p><p><strong><u>الاستخدام في البالغين من عمر 18 سنة فما أكبر</u> </strong></p><p><strong>لعلاج حرقة المعدة المسببة بواسطة مرض الارتجاع المعدى المريئي:</strong></p><p>- إذا وجد الطبيب عندك ضرر بسيط فى أنبوب الطعام (المرئ)، تكون الجرعة المعتادةهى 40 ملجم مرة واحدة يوميا لمدة 4 أسابيع. وفى حالة عدم التئام المرئ قد يوصى طبيبك المعالج باستمرارك فى تناول نفس الجرعة لمدة 4 أسابيع أخرى.</p><p>- فى حالة التئام المرئ، تكون الجرعة الموص بها هى كبسولة واحدة من إيزورا 20 ملجم مرة واحدةيوميا.</p><p>- فى حالة عدم وجود ضرر بالمرئ، تكون الجرعة المعتادة هى كبسولة واحدة من إيزورا 20 ملجم مرة واحدة يوميا. وبمجرد أن تتم السيطرة على الحالة، قد يخبرك الطبيب بتناول الدواء عند الحاجة، صعودا إلى كبسولة واحدة من إيزورا 20 ملجم يوميا كحد أقصى.</p><p>- إذا كنت تعانى من مشاكل حادة بالكبد، فقديصف لك الطبيب المعالج جرعة أقل</p><p><strong>. لعلاج التقرحات الناتجة عن الإصابة بالعدوى البكتيرية هيليكوباكتر بيلورى والحد من عودتها مرة أخرى:</strong></p><p>- الجرعة الموصي بهاهى كبسولة واحدة من إيزورا 20 ملجم مرتين يوميا لمدة أسبوع.</p><p>- وسوف يصف لك الطبيب المعالج تناول مضادات حيوية مثل أموكسيسيللين وكلاريثروميسين.</p><p><strong>لعلاج تقرحات المعدة الناتجة عن استخدام مضادات الالتهاب غير الاستيرويدية:</strong></p><p>- الجرعة الموصي بها هي كبسولة واحدة من إيزورا 20 ملجم مرة واحدة يوميا لمدة تتراوح ما بين 4 إلى 8 أسابيع.</p><p><strong>لمنع الإصابة بتقرحات المعدة أثناء تناول مضادات الالتهاب غير الاستيرويدية: -</strong></p><p>الجرعة الموصي بها هي كبسولة واحدة من إيزورا 20 ملجم مرة واحدة يوميا.</p><p>&nbsp;</p><p><strong>لعلاج زيادة إنتاج الحمض فى المعدة بسبب نمو فى البنكرياس (وهى ظاهرة تسمى زولينجر- إليسون):</strong></p><p>- الجرعة الموصى&nbsp;بهاهى كبسولة واحدة من إيزورا 40 ملجم مرتين يوميا.</p><p>- وسوف يقوم طبيبك المعالج بضبط الجرعة حسب احتياجك وسيقرر أيضا المدة الزمنية للعلاج. علما بأن الجرعة القصوى هى 80 ملجم مرتين يوميا.</p><p>&nbsp;</p><p><strong>العلاج طويل الأمد بعد منع إعادة النزيف من القرح باستخدام إيزوميبرازول في الوريد:</strong></p><p>- الجرعة الموصى بها هي كبسولة واحدة من إيزورا 40 ملجم مرة واحدة في اليوم لمدة 4 أسابيع.&nbsp;</p><p><u><strong>الاستخدام في المراهقين من عمر 12 سنة فما أكبر</strong></u></p><p><strong>لعلاج حرقة المعدة المسببة بواسطة مرض الارتجاع المعدى المريئي:</strong></p><p><strong>-</strong> إذا وجد الطبيب عندك ضرر بسيط فى أنبوب الطعام (المرئ)، تكون الجرعة المعتادة هى كبسولة واحدة من إيزورا 40 ملجم المقاومة لتأثير المعدة مرة واحدة يوميا لمدة 4 أسابيع. وفى حالة عدم التئام المرئ قد يوصى طبيبك المعالج باستمرارك فى تناول نفس الجرعة لمدة 4 أسابيع أخرى.</p><p>- فى حالة التئام المرئ، تكون الجرعة الموص بها هى كبسولة واحدة من إيزورا 20 ملجم المقاومة لتأثير المعدة مرة واحدة يوميا.</p><p>- فى حالة عدم وجود ضرر بالمرئ، تكون الجرعة المعتادة هى كبسولة واحدة من إيزورا 20 ملجم المقاومة لتأثير المعدة مرة واحدة يوميا.</p><p>- إذا كنت تعانى من مشاكل حادة بالكبد، فقد يصف لك الطبيب المعالج جرعة أقل.</p><p><strong>. لعلاج التقرحات الناتجة عن الإصابة بالعدوى البكتيرية هيليكوباكتر بيلورى والحد من عودتها مرة أخرى:</strong></p><p>- الجرعة الموصي بها هى كبسولة واحدة من إيزورا 20 ملجم المقاومة لتأثير المعدة مرتين يوميا لمدة أسبوع.</p><p>- وسوف يصف لك الطبیب المعالج تناول مضادات حيوية مثل أموكسيسيللين وكلاريثروميسين.</p><p><strong>تناول هذا الدواء</strong></p><p>- يمكنك تناول علاجك من هذه الكبسولات فى أى وقت من اليوم.</p><p>-يمكنك تناول علاجك من هذه الكبسولات مع الطعام أو على معدة خالية.</p><p>- قم بابتلاع الكبسولة كاملة مع شرب الماء. لا تقم بمضغ أو تكسير الكبسولات أو محتوياتها. وذلك لاحتواء الكبسولات على حبيبات مغلفة والتى تمنع تكسير الدواء بواسطة الحمض الموجود بالمعدة. لذلك من الضرورى عدم تكسير تلك الحبيبات.&nbsp;</p><p><strong>ما يجب عليك فعله عند وجود مشكلة بابتلاع هذه الكبسولات</strong></p><p>- إذا كانت لديك مشكلة فى ابتلاع هذه الكبسولات:</p><p>1 .افتح الكبسولة بعناية فوق كوب من المياه (غير الغازية) وقم بتفريغ محتوى الكبسولة (الحبيبات) في الكوب الزجاجي.</p><p>لا تستخدم أي سوائل أخرى.</p><p>2 .قم بالتقليب. ثم قم بشرب هذا الخليط على الفور أو في غضون 30 دقيقة. قم بتقليب الخليط دائما قبل شربه.</p><p>3 .للتأكد من شرب الدواء كاملا، اشطف الكوب جيدا بمقدار نصف كوب من الماء ثم اشربه. ولا تقم بمضغ أو تكسير القطع الصلبة المتبقية التى تحتوى على الدواء.</p><p>- إذا كنت غير قادر على الابتلاع مطلقا، يمكن مزج محتويات الكبسولة مع بعض الماء ووضع الخليط فى حقنة. ويمكن بعد ذلك أن تعطى لك من خلال أنبوب إلى المعدة مباشرة (&quot;أنبوب المعدة&quot;).</p><p><strong>فى حالة تناولك لجرعة من إيزورا أكثر مما ينبغى&nbsp;</strong></p><p>إذا تناولت جرعة من إيزورا أكثر مما وصفه طبيبك لك، تحدث إلى طبيبك المعالج أو الصيدلى مباشرة.</p><p><strong>فى حالة نسيانك لتناول الجرعة من إيزورا</strong></p><p>- فى حالة نسيانك لتناول الجرعة من إيزورا، قم بتناول الجرعة وقتما تتذكر. ومع ذلك إذا كان هذا الوقت قريبا من وقت تناول الجرعة التالية، تخطى الجرعة المفقودة.</p><p>- لا تقم بمضاعفة الجرعة (تناول جرعتين فى نفس الوقت) لتعويض الجرعة المفقودة.</p><p>إذا كانت لديك أي أسئلة أخرى عن استخدام هذا الدواء، فضلا قم بسؤال طبيبك أو الصيدلي.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية،إيزورا قد يسبب أعراض جانبية ، وإن لم تكن تحدث لكل من يتناول هذا الدواء. إذا لاحظت ظهور أى من الأعراض الجانبية الخطيرة الآتية، توقف عن تناول إيزورا وتواصل مع طبيبك المعالج فورا:</p><p>- أزيز مفاجئ أو تورم فى الشفتين أو اللسان والحلق أو الجسم أو الطفح الجلدى أو الإغماء أو صعوبة في البلع (تفاعلات تحسسية شديدة).</p><p>- احمرار الجلد مع ظهور بثور أو تقشير. قديكون هناك أيضا بثور شديدة ونزيف في الشفتين والعينين والفم والأنف والأعضاء التناسلية. والتى قد يمكن أن تكون مايسمى &quot;متلازمة ستيفنز جونسون&quot; أو &quot;انحلال البشرة السامة&quot;.</p><p>- اصفرار الجلد والبول الغامق اللون والإرهاق والتى قد تكون أعراض لمشاكل بالكبد.&nbsp;</p><p>هذه التأثيرات نادرة الحدوث، والتى تصيب أقل من واحد لكل 1000 شخص.</p><p>أعراض جانبية أخرى وتشمل:</p><p><strong>شائعة (من الممكن أن تصیب أقل من واحد لكل 10 أشخاص):</strong></p><p>- صداع.</p><p>- تأثيرات على المعدة أو القناة الهضمية: ألم بالمعدة، إمساك أو إسهال،ريح (انتفاخ).</p><p>- الشعور بالإعياء (غثيان) أو التقيؤ.</p><p><strong>غير شائعة (من الممكن أن تصيب أقل من واحد لكل 100 شخص):</strong></p><p>- تورم فى القدمين والكاحلين.</p><p>- اضطرابات فى النوم (الأرق).</p><p>- دوخة، الشعور بالوخز مثل &quot;الإبر و الدبابيس&quot;، الشعور بالنعاس.</p><p>-الشعور بالدوار.</p><p>- جفاف الحلق.</p><p>- تغيرات في اختبار الدم التي&nbsp;تتحقق من مدى كفاءة عمل الكبد. - طفح جلدى وطفح متكتل (الشرى) وحكة في الجلد.</p><p>- كسر في عظام الفخذ، الرسغ أو العمود الفقري (إذا تم استخدام إيزورا بجرعات عالية ولمدة طويلة).</p><p>&nbsp;</p><p><strong>نادرة الحدوث (من الممكن أن تصيب أقل من 1 لكل 1000 شخص):</strong></p><p>- مشاكل بالدم مثل نقص فى عدد خلایا الدم البیضاء أوالصفائح الدمویة. مما قد یسبب ضعف أو كدمات أو زیادة احتمالیة الإصابة بالعدوى.</p><p>- نقص فى مستوى الصودیوم بالدم. مما قد یسبب ضعف أو علة (تقیؤ) وتشنجات.</p><p>- الشعور بالاضطراب أو عدم التركیز أو الاكتئاب.</p><p>- تغيرات فى حاسة التذوق.</p><p>- مشاكل في الإبصار مثل عدم وضوح الرؤية</p><p>- الشعور المفاجئ بالأزيز أو قصور فى التنفس (تشنج فى القصبات الهوائية).</p><p>- التهابات داخل الفم.</p><p>- عدوى فطرية تسمى &quot; مرض القلاع&quot; والتى قد تصيب القناة الهضمية.</p><p>- مشاكل بالكبد، وتشمل الصفراء والتى تسبب اصفرار الجلد والبول قاتم اللون والتعب.</p><p>- تساقط الشعر (الصلع).</p><p>- الطفح الجلدى عند التعرض لآشعة الشمس.</p><p>- ألم بالمفاصل أو ألم بالعضلات.</p><p>- شعور عام بعدم الارتياح والخمول.</p><p>- زيادة التعرق.<strong> </strong></p><p><strong>نادرة جدا (من الممكن أن تصیب أقل من 1 لكل 000,10 شخص):</strong></p><p>- مشاكل بالدم مثل فقدان خلايا الدم البيضاء. - العدوانية.</p><p>- رؤية أو الإحساس أو سماع أشياء غير موجودة (الهلوسة).</p><p>- مشاكل حادة بالكبد والتى تؤدى إلى فشل الكبد والتهاب فى المخ.</p><p>- ظهور مفاجئ لطفح جلدى شديد أو تقرحات أو تقشير الجلد. والذى قد يصاحبه ارتفاع فى درجة الحرارة وآلام بالمفاصل (حمامي متعددة الأشكال أو متلازمة ستيفنز جونسون أو انحلال البشرة السمي).</p><p>- ضعف بالعضلات.</p><p>- مشاكل حادة بالكلى.</p><p>- تضخم الثديين عند الرجال.</p><p><strong>معدل التكرار غير معلوم (لا يمكن تقدير معدل التكرار من خلال البيانات المتاحة):</strong></p><p><strong>- </strong>إذا كنت تتناول إيزورا لقترة تتجاوز الثلاثة أشهر فمن الممكن أن تتعرض لنقص فى مستوى الماغنسيوم بالدم. علما بأن النقص فى مستوى الماغنسيوم بالدم قد يظهر فى شكل إرهاق وتقلصات العضلات اللاإرادي وارتباك وتشنجات ودوخة و زيادة معدل ضربات القلب. إذا تعرضت لأى من هذه الأعراض، فضلا أخبر طبيبك المعالج&nbsp;فورا. النقص فى مستوى الماغنسيوم بالدم قد يؤدى أيضا إلى انخفاض فى مستوى البوتاسيوم أوالكالسيوم فى الدم. لذلك قد يقرر طبيبك المعالج إجراء فحوصات منتظمة للدم وذلك لرصد مستويات الماغنسيوم فى الدم لديك.</p><p>- التهاب في الأمعاء (ممايؤدي إلى الإسهال).</p><p>- الطفح الجلدي، وربما يعانون من الام في المفاصل.</p><p>إيزورا فى حالات نادرة جدا قد يؤثر على خلايا الدم البيضاء مما يسبب نقص فى المناعة. إذا تعرضت للإصابة بعدوى مصحوبة بأعراض مثل الحمى المصحوبة بانخفاض حاد فى الحالة العامة أو الحمى المصحوبة بالتهاب موضعى مثل ألم فى الرقبة أو الحلق أو الفم أو صعوبة فى التبول،يجب عليك استشارة الطبيب فى أقرب وقت ممكن بحيث يمكن استبعاد عدم وجود خلايا الدم البيضاء (ندرة المحببات) من خلال فحص الدم. وسيكون من الضرورى فى ذلك الوقت إخبار طبيبك المعالج بشأن الأدوية التى تتناولها.</p><p><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p>إذا ظهرت عليك أي أعراض جانبية، قم بالتحدث مع طبيبك أو الصيدلي أو الممرضة. ويشمل ذلك أي أعراض جانبية ُ محتملة غير المدرجة في هذه النشرة. يمكنك أيضا الإبلاغ عن الأعراض الجانبية مباشرة عبر المركز الوطني للتيقظ والسلامة الدوائية. يمكنك من خلال الإبلاغ عن الأعراض الجانبية أن تساعد في توفير المزيد من المعلومات حول سلامة هذا الدواء.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>- يحفظ بعيدا عن متناول ونظر الأطفال.</p><p>- لا تستعمل هذا الدواء بعد انتهاء تاريخ الصلاحية المدون على العبوة أو الشريط. علما بأن تاريخ الصلاحية يشير إلى آخر يوم فى الشهر المذكور على العبوة.</p><p>- لا يحفظ فى درجة حرارة أعلى من 30 درجة مئوية. يتم تخزينه في العبوة الأصلية لحمايته من الرطوبة</p><p>. - لا تتخلص من أى دواء عبر مياه الصرف الصحيه والنفايات المنزلية. فضلا إستشر الصيدلى عن كيفية التخلص من الأدوية التى لم تعد تستخدم. فقد تساعد هذه التدابير على حماية البيئة.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>- المادة الفعالة هي إیزومیبرازول.</p><p>كبسولات إيزوميبرازول متوفرة في اثنين من التركيزات والتي تحتوي على 20 ملجم أو 40 ملجم من إيزوميبرازول(على شكل ملح الصوديوم).</p><p>- المكونات الأخرى :</p><p><u>محتوى الكبسولة: </u></p><p>دوائرالسكر (التي تحتوي على نشا الذرة والسكروز)، ميثيل السليلوز، التلك،وثاني أكسيد التيتانيوم (171-E ،(أحادي ستيارات الجلسرين، بوليسوربات 80 ،حمض إيثيل ميثا كريليك اكريليت كوبوليمر (1:1)التشتت %30 (التي تحتوي على سلفات لوريل الصوديوم، بوليسوربات 80 - وحمض إيثيل ميثا كريليك اكريليت كوبوليمر)،سترات ثلاثى الإيثيل و 20 %مستحلب من أحادي ستيارات الجلسرين، سترات ثلاثى الإيثيل وبوليسوربات-80 .</p><p><u>غلاف الكبسولة:</u></p><p>الكاراجينان، كلوريدالبوتاسيوم، وأكسيد الحديد الأحمر (172-E )، تابوكسید التيتانيوم (171-E ), هيدروكسي بروبيل ميثيل سيللوز، وحبر الطباعة) التي تحتوي على اللك، وهيدروكسيد البوتاسيوم وأكسيد الحديد الأسود (E172&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>- إيزورا 20 ملجم كبسولات صلبة لديها غطاء وردي غير شفاف وجسم، حجم4 ،مطبوعة، تحتوي على حبيبات كروية.</p><p>- إيزورا 40 ملجم كبسولات صلبة لديها غطاء وردي غير شفاف وجسم، حجم2 ، مطبوعة،تحتوي على حبيبات كروية.</p><p>إيزورا 20 ملجم متوفر في: ألومنيوم / شرائط من الألومنيوم: 14و 28 كبسولة.</p><p>إيزورا 40 ملجم متوفر في: ألومنيوم / شرائط من الألومنيوم: 14و 28 كبسولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>المصنع</strong></p><p>توا فارماسيتوكال أوروبا،</p><p>اس ال دي سانت مارتي75-97</p><p>08107 مارتوريليس ، برشلونة ، اسبانيا</p><p>لصالح</p><p>&nbsp;الدوائية مصنع الادوية بالقصيم</p><p>المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            فبراير 2020. 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                EZORA 20 mg gastro-resistant capsules, hard 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each gastro-resistant capsule contains 20 mg of esomeprazole (as sodium salt).
Excipients with known effect:
Each capsule contains approximately 20.0 – 22.9 mg of sucrose.
For the full list of excipients, see section 6.1. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gastro-resistant capsule, hard
Capsules with an opaque pink cap and body, size 4, printed, containing spherical pellets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>EZORA capsules are indicated for: </u></p><p>Gastroesophageal Reflux Disease (GERD)</p><p>- treatment of erosive reflux esophagitis</p><p>- long-term management of patients with healed esophagitis to prevent relapse</p><p>- symptomatic treatment of gastroesophageal reflux disease (GERD)</p><p>In combination with appropriate antibacterial therapeutic regimens for the eradication of Helicobacter pylori and</p><p>- healing of Helicobacter pylori associated duodenal ulcer and</p><p>- prevention of relapse of peptic ulcers in patients with Helicobacter pylori associated ulcers.</p><p>&nbsp;</p><p>Patients requiring continued NSAID therapy</p><p>&minus; Healing of gastric ulcers associated with NSAID therapy.</p><p>&minus; Prevention of gastric and duodenal ulcers associated with NSAID therapy, in patients at risk.</p><p>Treatment of Zollinger Ellison Syndrome</p><p><u>Adolescents from the age of 12 years for: </u></p><p>Gastro-esophageal Reflux Disease (GERD)</p><p>- treatment of erosive reflux esophagitis</p><p>- long-term management of patients with healed esophagitis to prevent relapse</p><p>- symptomatic treatment of gastro-esophageal reflux disease (GERD)</p><p>In combination with antibiotics in treatment of duodenal ulcer caused by Helicobacter pylori</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology </u></p><p><u>Adults</u></p><p>Gastroesophageal Reflux Disease (GERD)</p><p>- treatment of erosive reflux esophagitis 40 mg once daily for 4 weeks. An additional 4 weeks treatment is recommended for patients in whom esophagitis has not healed or who have persistent symptoms.</p><p>- long-term management of patients with healed esophagitis to prevent relapse 20 mg once daily.</p><p>- symptomatic treatment of gastroesophageal reflux disease (GERD) 20 mg once daily in patients without esophagitis. If symptom control has not been achieved after 4 weeks, the patient should be further investigated. Once symptoms have resolved, subsequent symptom control can be achieved using 20 mg once daily. In adults, an on demand regimen taking 20 mg once daily, when needed, can be used. In NSAID treated patients at risk of developing gastric and duodenal ulcers, subsequent symptom control using an on demand regimen is not recommended.</p><p><em>In combination with appropriate antibacterial therapeutic regimens for the eradication of Helicobacter pylori and </em></p><p>- healing of Helicobacter pylori associated duodenal ulcer and</p><p>- prevention of relapse of peptic ulcers in patients with Helicobacter pylori associated ulcers. 20 mg EZORA with 1 g amoxicillin and 500 mg clarithromycin, all twice daily for 7 days.</p><p><em>Patients requiring continued NSAID therapy </em></p><p>&minus; Healing of gastric ulcers associated with NSAID therapy: The usual dose is 20 mg once daily. The treatment duration is 4-8 weeks.</p><p>&minus; Prevention of gastric and duodenal ulcers associated with NSAID therapy in patients at risk: 20 mg once daily.</p><p><em>Treatment of Zollinger Ellison Syndrome </em></p><p>The recommended initial dosage is EZORA40 mg twice daily. The dosage should then be individually adjusted and treatment continued as long as clinically indicated. Based on the clinical data available, the majority of patients can be controlled on doses&nbsp;between 80 to 160 mg esomeprazole daily. With doses above 80 mg daily, the dose should be divided and given twice daily.</p><p><em>Special Populations </em></p><p><em>Renal impairment</em></p><p>Dose adjustment is not required in patients with impaired renal function. Due to limited experience in patients with severe renal insufficiency, such patients should be treated with caution (see section 5.2).</p><p><em>Hepatic impairment </em></p><p>Dose adjustment is not required in patients with mild to moderate liver impairment. For patients with severe liver impairment, a maximum dose of 20 mg EZORA should not be exceeded (see section 5.2).</p><p><em>Elderly</em></p><p>Dose adjustment is not required in the elderly.</p><p>Paediatric population</p><p><u><em>Adolescents from the age of 12 years</em></u></p><p>Gastroesophageal Reflux Disease (GERD)</p><p><u>&minus; treatment of erosive reflux esophagitis</u> 40 mg once daily for 4 weeks An additional 4 weeks treatment is recommended for patients in whom esophagitis has not healed or who have persistent symptoms.</p><p><u>&minus; long-term management of patients with healed esophagitis to prevent relapse</u> 20 mg once daily.</p><p><u>&minus; symptomatic treatment of gastroesophageal reflux disease (GERD) </u>20 mg once daily in patients without esophagitis. If symptom control has not been achieved after 4 weeks, the patient should be further investigated. Once symptoms have resolved, subsequent symptom control can be achieved using 20 mg once daily.</p><p><em>Treatment of duodenal ulcer caused by Helicobacter pylori </em></p><p>When selecting appropriate combination therapy, consideration should be given to official national, regional and local guidance regarding bacterial resistance, duration of treatment (most commonly 7 days but sometimes up to 14 days), and appropriate use of antibacterial agents. The treatment should be supervised by a specialist.</p><p>The posology recommendation is:</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td>Weight</td><td>Posology</td></tr><tr><td>30 - 40 kg</td><td>Combination with two antibiotics: EZORA20 mg, amoxicillin 750 mg and clarithromycin 7.5 mg/kg body weight are all administered together twice daily for one week.</td></tr><tr><td>&gt; 40 kg</td><td>Combination with two antibiotics: EZORA20 mg, amoxicillin 1 g and clarithromycin 500 mg are all administered together twice daily for one week.</td></tr></tbody></table><p><u>Children below the age of 12 years </u></p><p>For posology in patients aged 1 to 11 reference is made to the esomeprazole sachet SmPC.</p><p><u>Method of administration</u></p><p>The capsules should be swallowed whole with liquid. The capsules should not be chewedor crushed. For patients who have difficulty in swallowing, the capsules can also bedispersed in half a glass of noncarbonated water. No other liquids should be used asthe enteric coating may be dissolved. Stir until the capsules disintegrate and drink theliquid with the pellets immediately or within 30 minutes. Rinse the glass with half aglass of water and drink. The pellets must not be chewed or crushed.</p><p>For patients who cannot swallow, the capsules can be dispersed in non-carbonated water and administered through a gastric tube. It is important that the appropriateness of the selected syringe and tube is carefully tested. For preparation and administration instructions see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance, substituted benzimidazoles or any of the excipients listed in
section 6.1.
Esomeprazole should not be used concomitantly with nelfinavir (see section 4.5). 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the presence of any alarm symptom (e.g. significant unintentional weight loss, recurrent vomiting, dysphagia, haematemesis or melaena) and when gastric ulcer is suspected or present, malignancy should be excluded, as treatment with esomeprazole may alleviate symptoms and delay diagnosis.</p><p><u>Long term use </u></p><p>Patients on long-term treatment (particularly those treated for more than a year) should be kept under regular surveillance.</p><p><u>On demand treatment </u></p><p>Patients on on-demand treatment should be instructed to contact their physician if their symptoms change in character. When prescribing esomeprazole for on demand therapy, the implications for interactions with other pharmaceuticals, due to fluctuating plasma concentrations of esomeprazole should be considered (see section 4.5).</p><p><u>Helicobacter pylori eradication </u></p><p>When prescribing esomeprazole for eradication of Helicobacter pylori possible drug interactions for all components in the triple therapy should be considered. Clarithromycin is a potent inhibitor of CYP3A4 and hence contraindications and interactions for clarithromycin should be considered when the triple therapy is used in patients concurrently taking other drugs metabolised via CYP3A4 such as cisapride.</p><p><u>Gastrointestinal infections </u></p><p>Treatment with proton pump inhibitors may lead to slightly increased risk of gastrointestinal infections such as Salmonella and Campylobacter (see section 5.1).</p><p><u>Absorption of vitamin B12</u></p><p>Esomeprazole, as all acid-blocking medicines, may reduce the absorption of vitamin B12 (cyanocobalamin) due to hypo- or achlorhydria. This should be considered in patients with reduced body stores or risk factors for reduced vitamin B12 absorption on long-term therapy.</p><p><u>Hypomagnesaemia </u></p><p>Severe hypomagnesaemia has been reported in patients treated with PPIs like esomeprazole for at least three months, and in most cases for a year. Serious manifestations of hypomagnesaemia such as fatigue, tetany, delirium, convulsions, dizziness and ventricular arrhythmia can occur but they may begin insidiously and be overlooked. In most affected patients, hypomagnesaemia improved after magnesium replacement and discontinuation of the PPI. For patients expected to be on prolonged treatment or who take PPIs with digoxin or drugs that may cause hypomagnesaemia (e.g., diuretics), healthcare professionals should consider measuring magnesium levels before starting PPI treatment and periodically during treatment.</p><p><u>Risk of fracture </u></p><p>Proton pump inhibitors, especially if used in high doses and over long durations (&gt;1 year), may modestly increase the risk of hip, wrist and spine fracture, predominantly in the elderly or in presence of other recognised risk factors. Observational studies suggest that proton pump inhibitors may increase the overall risk of fracture by 10&ndash;40%. Some of this increase may be due to other risk factors. Patients at risk of osteoporosis should receive care according to current clinical guidelines and they should have an adequate intake of vitamin D and calcium.</p><p><u>Subacute cutaneous lupus erythematosus (SCLE) </u></p><p>Proton pump inhibitors are associated with very infrequent cases of SCLE. If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the&nbsp;patient should seek medical help promptly and the health care professional should consider stopping EZORA. SCLE after previous treatment with a proton pump inhibitor may increase the risk of SCLE with other proton pump inhibitors.&nbsp;</p><p><u>Combination with other medicinal products </u></p><p>Co-administration of esomeprazole with atazanavir is not recommended (see section 4.5). If the combination of atazanavir with a proton pump inhibitor is judged unavoidable, close clinical monitoring is recommended in combination with an increase in the dose of atazanavir to 400 mg with 100 mg of ritonavir; esomeprazole 20 mg should not be exceeded. Esomeprazole is a CYP2C19 inhibitor. When starting or ending treatment with esomeprazole, the potential for interactions with drugs metabolised through CYP2C19 should be considered. An interaction is observed between clopidogrel and esomeprazole (see section 4.5). The clinical relevance of this interaction is uncertain. As a precaution, concomitant use of esomeprazole and clopidogrel should be discouraged. When prescribing esomeprazole for on demand therapy, the implications for interactions with other pharmaceuticals, due to fluctuating plasma concentrations of esomeprazole should be considered. See section 4.5.</p><p><u>Sucrose</u></p><p>This medicinal product contains sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.</p><p><u>Interference with laboratory tests </u></p><p>Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours. To avoid this interference, esomeprazole treatment should be stopped for at least 5 days before CgA measurements (see section 5.1). If CgA and gastrin levels have not returned to reference range after initial measurement, measurements should be repeated 14 days after cessation of proton pump inhibitor treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction studies have only been performed in adults.</p><p><u>Effects of esomeprazole on the pharmacokinetics of other drugs </u></p><p><u>Protease inhibitors </u></p><p>Omeprazole has been reported to interact with some protease inhibitors. The clinical importance and the mechanisms behind these reported interactions are not always known. Increased gastric pH during omeprazole treatment may change the absorption of the protease inhibitors. Other possible interaction mechanisms are via inhibition of CYP 2C19.</p><p>For atazanavir and nelfinavir, decreased serum levels have been reported when given&nbsp;together with omeprazole and concomitant administration is not recommended. Coadministration of omeprazole (40 mg once daily) with atazanavir 300 mg/ritonavir 100 mg to healthy volunteers resulted in a substantial reduction in atazanavir exposure (approximately 75% decrease in AUC, Cmax and Cmin). Increasing the atazanavir dose to 400 mg did not compensate for the impact of omeprazole on atazanavir exposure. The co-administration of omeprazole (20 mg qd) with atazanavir 400 mg/ritonavir 100 mg to healthy volunteers resulted in a decrease of approximately 30% in the atazanavir exposure as compared with the exposure observed with atazanavir 300 mg/ritonavir 100 mg qd without omeprazole 20 mg qd. Co-administration of omeprazole (40 mg qd) reduced mean nelfinavir AUC, Cmax and Cmin by 36&ndash;39 % and mean AUC, Cmax and Cmin for the pharmacologically active metabolite M8 was reduced by 75-92%. Due to the similar pharmacodynamic effects and pharmacokinetic properties of omeprazole and esomeprazole, concomitant administration with esomeprazole and atazanavir is not recommended (see section 4.4) and concomitant administration with esomeprazole and nelfinavir is contraindicated (see section 4.3). For saquinavir (with concomitant ritonavir), increased serum levels (80-100%) have been reported during concomitant omeprazole treatment (40 mg qd). Treatment with omeprazole 20 mg qd had no effect on the exposure of darunavir (with concomitant ritonavir) and amprenavir (with concomitant ritonavir). Treatment with esomeprazole 20 mg qd had no effect on the exposure of amprenavir (with and without concomitant ritonavir). Treatment with omeprazole 40 mg qd had no effect on the exposure of lopinavir (with concomitant ritonavir).</p><p><u>Methotrexate</u></p><p>When given together with PPIs, methotrexate levels have been reported to increase in some patients. In high-dose methotrexate administration a temporary withdrawal of esomeprazole may need to be considered.</p><p><u>Tacrolimus</u></p><p>Concomitant administration of esomeprazole has been reported to increase the serum levels of tacrolimus. A reinforced monitoring of tacrolimus concentrations as well as renal function (creatinine clearance) should be performed, and dosage of tacrolimus adjusted if needed.</p><p><u>Medicinal products with pH dependent absorption </u></p><p>Gastric acid suppression during treatment with esomeprazole and other PPIs might decrease or increase the absorption of medicinal products with a gastric pH dependent absorption. As with other medicinal products that decrease intragastric acidity, the absorption of medicinal products such as ketoconazole, itraconazole and erlotinib can decrease and the absorption of digoxin can increase during treatment with esomeprazole. Concomitant treatment with omeprazole (20 mg daily) and digoxin in healthy subjects increased the bioavailability of digoxin by 10% (up to 30% in two out of ten subjects). Digoxin toxicity has been rarely reported. However, caution should be exercised when esomeprazole is given at high doses in elderly patients. Therapeutic drug monitoring of digoxin should then be reinforced.</p><p>&nbsp;</p><p><u>Medicinal products metabolised by CYP2C19</u></p><p>Esomeprazole inhibits CYP2C19, the major esomeprazole metabolising enzyme. Thus, when esomeprazole is combined with drugs metabolised by CYP2C19, such as diazepam, citalopram, imipramine, clomipramine, phenytoin etc., the plasma concentrations of these drugs may be increased and a dose reduction could be needed. This should be considered especially when prescribing esomeprazole for on demand therapy.</p><p><u>Diazepam</u></p><p>Concomitant administration of 30 mg esomeprazole resulted in a 45 % decrease in clearance of the CYP2C19 substrate diazepam.</p><p><u>Phenytoin</u></p><p>Concomitant administration of 40 mg esomeprazole resulted in a 13 % increase in trough plasma levels of phenytoin in epileptic patients. It is recommended to monitor the plasma concentrations of phenytoin when treatment with esomeprazole is introduced or withdrawn.</p><p><u>Voriconazole</u></p><p>Omeprazole (40 mg once daily) increased voriconazole (a CYP2C19 substrate) Cmax and AUC&tau; by 15 % and 41 %, respectively.</p><p><u>Cilostazol</u></p><p>Omeprazole as well as esomeprazole act as inhibitors of CYP2C19. Omeprazole, given in doses of 40 mg to healthy subjects in a cross-over study, increased Cmax and AUC for cilostazol by 18% and 26% respectively, and one of its active metabolites by 29% and 69% respectively.</p><p><u>Cisapride</u></p><p>In healthy volunteers, concomitant administration of 40 mg esomeprazole resulted in a 32% increase in area under the plasma concentration-time curve (AUC) and a 31% prolongation of elimination half-life (t1/2) but no significant increase in peak plasma levels of cisapride. The slightly prolonged QTc interval observed after administration of cisapride alone, was not further prolonged when cisapride was given in combination with esomeprazole (see also section 4.4).</p><p><u>Warfarin</u></p><p>Concomitant administration of 40 mg esomeprazole to warfarin-treated patients in a clinical trial showed that coagulation times were within the accepted range. However, post-marketing, a few isolated cases of elevated INR of clinical significance have been reported during concomitant treatment. Monitoring is recommended when initiating and ending concomitant esomeprazole treatment during treatment with warfarin or other coumarin derivatives.</p><p><u>Clopidogrel </u></p><p>Results from studies in healthy subjects have shown a pharmacokinetic (PK)/ pharmacodynamic (PD) interaction between clopidogrel (300 mg loading dose/75 mg daily maintenance dose) and esomeprazole (40 mg p.o.daily) resulting in decreased exposure to the active metabolite of clopidogrel by an average of 40% and resulting in decreased maximum inhibition of (ADP induced) platelet aggregation by an average&nbsp;f 14%. When clopidogrel was given together with a fixed dose combination of esomeprazole 20 mg + ASA 81 mg compared to clopidogrel alone in a study in healthy subjects there was a decreased exposure by almost 40% of the active metabolite of clopidogrel. However, the maximum levels of inhibition of (ADP induced) platelet aggregation in these subjects were the same in the clopidogrel and the clopidogrel + the combined (esomeprazole + ASA) product groups. Inconsistent data on the clinical implications of a PK/PD interaction of esomeprazole in terms of major cardiovascular events have been reported from both observational and clinical studies. As a precaution concomitant use of clopidogrel should be discouraged.</p><p><u><em>Investigated medicinal products with no clinically relevant interaction </em></u></p><p><em>Amoxicillin and quinidine</em></p><p>Esomeprazole has been shown to have no clinically relevant effects on the pharmacokinetics of amoxicillin or quinidine.</p><p><em>Naproxen or rofecoxib</em></p><p>Studies evaluating concomitant administration of esomeprazole and either naproxen or rofecoxib did not identify any clinically relevant pharmacokinetic interactions during short-term studies.</p><p><u>Effects of other medicinal products on the pharmacokinetics of esomeprazole </u></p><p><u>Medicinal products which inhibit CYP2C19 and/or CYP3A4</u></p><p>Esomeprazole is metabolised by CYP2C19 and CYP3A4. Concomitant administration of esomeprazole and a CYP3A4 inhibitor, clarithromycin (500 mg b.i.d.), resulted in a doubling of the exposure (AUC) to esomeprazole. Concomitant administration of esomeprazole and a combined inhibitor of CYP2C19 and CYP3A4 may result in more than doubling of the esomeprazole exposure. The CYP2C19 and CYP3A4 inhibitor voriconazole increased omeprazole AUC by 280%. A dose adjustment of esomeprazole is not regularly required in either of these situations. However, dose adjustment should be considered in patients with severe hepatic impairment and if long-term treatment is indicated.</p><p><u>Medicinal products which induce CYP2C19 and/or CYP3A4</u></p><p>Drugs known to induce CYP2C19 or CYP3A4 or both (such as rifampicin and St. John&rsquo;s wort) may lead to decreased esomeprazole serum levels by increasing the esomeprazole metabolism.</p><p><u>Paediatric population</u></p><p>Interaction studies have only been performed in adults.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>For esomeprazole clinical data on exposed pregnancies are insufficient. With the racemic mixture, omeprazole, data on a larger number of exposed pregnancies from&nbsp;epidemiological studies indicate no malformative nor foetotoxic effect. Animal studies with esomeprazole do not indicate direct or indirect harmful effects with respect to embryonal/foetal development. Animal studies with the racemic mixture do not indicate direct or indirect harmful effects with respect to pregnancy, parturition or postnatal development. Caution should be exercised when prescribing to pregnant women. A moderate amount of data on pregnant women (between 300-1000 pregnancy outcomes) indicates no malformative or foeto/neonatal toxicity of esomeprazole. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).</p><p><u>Breastfeeding</u></p><p>It is not known whether esomeprazole is excreted in human breast milk. There is insufficient information on the effects of esomeprazole in newborns/infants. Esomeprazole should not be used during breast-feeding.</p><p><u>Fertility</u></p><p>Animal studies with the racemic mixture omeprazole, given by oral administration do not indicate effects with respect to fertility</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Esomeprazole has minor influence on the ability to drive and use machines. Adverse reactions such as dizziness (uncommon) and blurred vision (rare) has been reported (see section 4.8). If affected patients should not drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>Headache, abdominal pain, diarrhoea and nausea are among those adverse reactions that have been most commonly reported in clinical trials (and also from postmarketing use). In addition, the safety profile is similar for different formulations, treatment indications, age groups and patient populations. No dose-related adverse reactions have been identified.</p><p><u>Tabulated list of adverse reactions</u></p><p>The following adverse drug reactions have been identified or suspected in the clinical trials programme for esomeprazole and post-marketing. None was found to be doserelated. The reactions are classified according to frequency (very common &ge; 1/10; common &ge; 1/100 to &lt; 1/10; uncommon &ge; 1/1,000 to &lt; 1/100; rare &ge; 1/10,000 to &lt; 1/1,000; very rare &lt; 1/10,000; not known (cannot be estimated from the available data).</p><table cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>System Organ Class</strong></p></td><td><p><strong>Frequency</strong></p></td><td><p><strong>Undesirable Effect</strong></p></td></tr><tr><td rowspan="2"><p>Blood and lymphatic system disorders</p></td><td><p>Rare</p></td><td><p>Leukopenia, thrombocytopenia</p></td></tr><tr><td><p>Very rare</p></td><td><p>Agranulocytosis, pancytopenia</p></td></tr><tr><td><p>Immune system disorders</p></td><td><p>Rare</p></td><td><p>Hypersensitivity reactions e.g. fever, angioedema and anaphylactic reaction/shock</p></td></tr><tr><td rowspan="3"><p>Metabolism and nutrition disorders</p></td><td><p>Uncommon</p></td><td><p>Peripheral oedema</p></td></tr><tr><td><p>Rare</p></td><td><p>Hyponatraemia</p></td></tr><tr><td><p>Not known</p></td><td><p>Hypomagnesaemia (see section 4.4); severe hypomagnesaemia can correlate with hypocalcaemia</p></td></tr><tr><td rowspan="3"><p>Psychiatric disorders</p></td><td><p>Uncommon</p></td><td><p>Insomnia</p></td></tr><tr><td><p>Rare</p></td><td><p>Agitation, confusion, depression</p></td></tr><tr><td><p>Very rare</p></td><td><p>Aggression, hallucinations</p></td></tr><tr><td rowspan="3"><p>Nervous system disorders</p></td><td><p>Common</p></td><td><p>Headache</p></td></tr><tr><td><p>Uncommon</p></td><td><p>Dizziness, paraesthesia, somnolence</p></td></tr><tr><td><p>Rare</p></td><td><p>Taste disturbance</p></td></tr><tr><td><p>Eye disorders</p></td><td><p>Rare</p></td><td><p>Blurred vision</p></td></tr><tr><td><p>Ear and labyrinth disorders</p></td><td><p>Uncommon</p></td><td><p>Vertigo</p></td></tr><tr><td><p>Respiratory, thoracic and mediastinal disorders</p></td><td><p>Rare</p></td><td><p>Bronchospasm</p></td></tr><tr><td rowspan="4"><p>Gastrointestinal disorders</p></td><td><p>Common</p></td><td><p>Abdominal pain, constipation, diarrhoea, flatulence, nausea/vomiting, fundic gland polyps (benign)</p></td></tr><tr><td><p>Uncommon</p></td><td><p>Dry mouth</p></td></tr><tr><td><p>Rare</p></td><td><p>Stomatitis, gastrointestinal candidiasis</p></td></tr><tr><td><p>Not known</p></td><td><p>Microscopic colitis</p></td></tr><tr><td rowspan="3"><p>Hepatobiliary disorders</p></td><td><p>Uncommon</p></td><td><p>Increased liver enzymes</p></td></tr><tr><td><p>Rare</p></td><td><p>Hepatitis with or without jaundice</p></td></tr><tr><td><p>Very rare</p></td><td><p>Hepatic failure, encephalopathy in patients with pre-existing liver disease</p></td></tr><tr><td rowspan="4"><p>Skin and subcutaneous tissue disorders</p></td><td><p>Uncommon</p></td><td><p>Dermatitis, pruritus, rash, urticaria</p></td></tr><tr><td><p>Rare</p></td><td><p>Alopecia, photosensitivity</p></td></tr><tr><td><p>Very rare</p></td><td><p>Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN)</p></td></tr><tr><td><p>Not known</p></td><td><p>Subacute cutaneous lupus erythematosus (see section 4.4).</p></td></tr><tr><td rowspan="3"><p>Musculoskeletal and connective tissue disorders</p></td><td><p>Uncommon</p></td><td><p>Fracture of the hip, wrist or spine (see section 4.4)</p></td></tr><tr><td><p>Rare</p></td><td><p>Arthralgia, myalgia</p></td></tr><tr><td><p>Very rare</p></td><td><p>Muscular weakness</p></td></tr><tr><td><p>Renal and urinary disorders</p></td><td><p>Very rare</p></td><td><p>Interstitial nephritis; in some patients renal failure has been reported concomitantly</p></td></tr><tr><td><p>Reproductive system and breast disorders</p></td><td><p>Very rare</p></td><td><p>Gynaecomastia</p></td></tr><tr><td><p>General disorders and administration site conditions</p></td><td><p>&Acirc;&nbsp;rare</p></td><td><p>Malaise, increased sweating</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions </u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><table border="1" align="center" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p><strong>To report any sideeffect(s):</strong></p><p>&nbsp;The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662 o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is very limited experience to date with deliberate overdose. The symptoms described in connection with 280 mg were gastrointestinal symptoms and weakness. Single doses of 80 mg esomeprazole were uneventful. No specific antidote is known. Esomeprazole is extensively plasma protein bound and is therefore not readily dialyzable. As in any case of overdose, treatment should be symptomatic and general supportive measures should be utilised.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: proton pump inhibitor</p><p>ATC code: A02B C05</p><p>Esomeprazole is the S-isomer of omeprazole and reduces gastric acid secretion through a specific targeted mechanism of action. It is a specific inhibitor of the acid pump in the&nbsp;parietal cell. Both the R- and S-isomer of omeprazole have similar pharmacodynamic activity.</p><p><u>Mechanism of action </u></p><p>Esomeprazole is a weak base and is concentrated and converted to the active form in the highly acidic environment of the secretory canaliculi of the parietal cell, where it inhibits the enzyme H+K+-ATPase &ndash; the acid pump and inhibits both basal and stimulated acid secretion.</p><p><u>Pharmacodynamic effects </u></p><p>After oral dosing with esomeprazole 20 mg and 40 mg the onset of effect occurs within one hour. After repeated administration with 20 mg esomeprazole once daily for five days, mean peak acid output after pentagastrin stimulation is decreased 90% when measured 6-7 hours after dosing on day five. After five days of oral dosing with 20 mg and 40 mg of esomeprazole, intragastric pH above 4 was maintained for a mean time of 13 hours and 17 hours, respectively over 24 hours in symptomatic GERD patients. The proportion of patients maintaining an intragastric pH above 4 for at least 8, 12 and 16 hours respectively were for esomeprazole 20 mg 76 %, 54 % and 24 %. Corresponding proportions for esomeprazole 40 mg were 97 %, 92 % and 56 %. Using AUC as a surrogate parameter for plasma concentration, a relationship between inhibition of acid secretion and exposure has been shown. Healing of reflux esophagitis with esomeprazole 40 mg occurs in approximately 78 % of patients after four weeks, and in 93 % after eight weeks. One week treatment with esomeprazole 20 mg b.i.d. and appropriate antibiotics, results in successful eradication of H. pylori in approximately 90 % of patients. After eradication treatment for one week there is no need for subsequent monotherapy with antisecretory drugs for effective ulcer healing and symptom resolution in uncomplicated duodenal ulcers. In a randomized, double blind, placebo-controlled clinical study, patients with endoscopically confirmed peptic ulcer bleeding characterised as Forrest Ia, Ib, IIa or IIb (9 %, 43 %, 38 % and 10 % respectively) were randomized to receive esomeprazole solution for infusion (n=375) or placebo (n=389). Following endoscopic haemostasis, patients received either 80 mg esomeprazole as an intravenous infusion over 30 minutes followed by a continuous infusion of 8 mg per hour or placebo for 72 hours. After the initial 72 hour period, all patients received open-label 40 mg oral esomeprazole for 27 days for acid suppression. The occurrence of rebleeding within 3 days was 5.9 % in the esomeprazole treated group compared to 10.3 % for the placebo group. At 30 days posttreatment, the occurrence of rebleeding in the esomeprazole treated versus the placebo treated group was 7.7 % vs 13.6 %. During treatment with antisecretory drugs serum gastrin increases in response to the decreased acid secretion. Also Cg A increases due to decreased gastric acidity. The increased Cg A level may interfere with investigations for neuroendocrine tumours.</p><p>Available published evidence suggests that proton pump inhibitors should be discontinued between 5 days and 2 weeks prior to CgA measurements. This is to allow CgA levels that might be spuriously elevated following PPI treatment to return to reference range. An increased number of ECL cells possibly related to the increased serum gastrin levels, has been observed in both children and adults during long term treatment with esomeprazole. The findings are considered to be of no clinical significance. During long-term treatment with antisecretory drugs gastric glandular cysts have been reported to occur at a somewhat increased frequency. These changes are a physiological consequence of pronounced inhibition of acid secretion, are benign and appear to be reversible. Decreased gastric acidity due to any means including proton pump inhibitors, increases gastric counts of bacteria normally present in the gastrointestinal tract. Treatment with proton pump inhibitors may lead to slightly increased risk of gastrointestinal infections such as Salmonella and Campylobacter and, in hospitalised patients, possibly also Clostridium difficile.</p><p><u>Clinical efficacy </u></p><p>In two studies with ranitidine as an active comparator, esomeprazole showed better effect in healing of gastric ulcers in patients using NSAIDs, including COX-2 selective NSAIDs. In two studies with placebo as comparator, esomeprazole showed better effect in the prevention of gastric and duodenal ulcers in patients using NSAIDs (aged &gt;60 and/or with previous ulcer), including COX-2 selective NSAIDs.</p><p><u>Paediatric population</u></p><p>In a study in paediatric GERD patients (&lt;1 to 17 years of age) receiving long-term PPI treatment, 61 % of the children developed minor degrees of ECL cell hyperplasia with no known clinical significance and with no development of atrophic gastritis or carcinoid tumours.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption </u></p><p>Esomeprazole is acid labile and is administered orally as enteric-coated granules. In vivo conversion to the R-isomer is negligible. Absorption of esomeprazole is rapid, with peak plasma levels occurring approximately 1-2 hours after dose. The absolute bioavailability is 64 % after a single dose of 40 mg and increases to 89 % after repeated once-daily administration. For 20 mg esomeprazole the corresponding values are 50 % and 68 % respectively. Food intake both delays and decreases the absorption of esomeprazole although this has no significant influence on the effect of esomeprazole on intragastric acidity.</p><p><u>Distribution </u></p><p>The apparent volume of distribution at steady state in healthy subjects is approximately 0.22 l/kg body weight. Esomeprazole is 97% plasma protein bound.</p><p><u>Biotransformation</u></p><p>Esomeprazole is completely metabolised by the cytochrome P450 system (CYP). The major part of the metabolism of esomeprazole is dependent on the polymorphic CYP2C19, responsible for the formation of the hydroxy- and desmethyl metabolites of esomeprazole. The remaining part is dependent on another specific isoform, CYP3A4, responsible for the formation of esomeprazole sulphone, the main metabolite in plasma.</p><p><u>Elimination </u></p><p>The parameters below reflect mainly the pharmacokinetics in individuals with a functional CYP2C19 enzyme, extensive metabolisers. Total plasma clearance is about 17 l/h after a single dose and about 9 l/h after repeated administration. The plasma elimination half-life is about 1.3 hours after repeated once daily dosing. Esomeprazole is completely eliminated from plasma between doses with no tendency for accumulation during once-daily administration. The major metabolites of esomeprazole have no effect on gastric acid secretion. Almost 80% of an oral dose of esomeprazole is excreted as metabolites in the urine, the remainder in the faeces. Less than 1% of the parent drug is found in urine.</p><p><u>Linearity/non-linearity </u></p><p>The pharmacokinetics of esomeprazole has been studied in doses up to 40 mg b.i.d. The area under the plasma concentration-time curve increases with repeated administration of esomeprazole. This increase is dose-dependent and results in a more than dose proportional increase in AUC after repeated administration. This time- and dose-dependency is due to a decrease of first pass metabolism and systemic clearance probably caused by an inhibition of the CYP2C19 enzyme by esomeprazole and/or its sulphone metabolite.</p><p><u>Special patient populations </u></p><p><u>Poor metabolisers</u></p><p>Approximately 2.9 &plusmn; 1.5 % of the population lack a functional CYP2C19 enzyme and are called poor metabolisers. In these individuals the metabolism of esomeprazole is probably mainly catalysed by CYP3A4. After repeated once-daily administration of 40 mg esomeprazole, the mean area under the plasma concentration-time curve was approximately 100 % higher in poor metabolisers than in subjects having a functional CYP2C19 enzyme (extensive metabolisers). Mean peak plasma concentrations were increased by about 60 %. These findings have no implications for the posology of esomeprazole.</p><p><u>Gender</u></p><p>Following a single dose of 40 mg esomeprazole the mean area under the plasma concentration-time curve is approximately 30 % higher in females than in males. No gender difference is seen after repeated once-daily administration. These findings have no implications for the posology of esomeprazole.</p><p><u>Hepatic impairment </u></p><p>The metabolism of esomeprazole in patients with mild to moderate liver dysfunction may be impaired. The metabolic rate is decreased in patients with severe liver dysfunction resulting in a doubling of the area under the plasma concentration-time curve of esomeprazole. Therefore, a maximum of 20 mg should not be exceeded in patients with severe dysfunction. Esomeprazole or its major metabolites do not show any tendency to accumulate with once-daily dosing.</p><p><u>Renal impairment</u></p><p>No studies have been performed in patients with decreased renal function. Since the kidney is responsible for the excretion of the metabolites of esomeprazole but not for the elimination of the parent compound, the metabolism of esomeprazole is not expected to be changed in patients with impaired renal function.</p><p><u>Elderly</u></p><p>The metabolism of esomeprazole is not significantly changed in elderly subjects (71- 80 years of age).</p><p><u>Paediatric population</u></p><p>Adolescents 12-18 years: Following repeated dose administration of 20 mg and 40 mg esomeprazole, the total exposure (AUC) and the time to reach maximum plasma drug concentration (tmax) in 12 to 18 year-old was similar to that in adults for both esomeprazole doses.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development. Adverse reactions not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels and with possible relevance to clinical use were as follows: Carcinogenicity studies in the rat with the racemic mixture have shown gastric ECL cell hyperplasia and carcinoids. These gastric effects in the rat are the result of sustained, pronounced hypergastrinaemia secondary to reduced production of gastric acid and are observed after long-term treatment in the rat with inhibitors of gastric acid secretion.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Capsule content: </u></p><p>Sugar Spheres (containing maize starch and sucrose)</p><p>Methyl cellulose</p><p>Talc</p><p>Titanium Dioxide (E-171)</p><p>Glycerol Monostearate</p><p>Polysorbate-80</p><p>Methacrylic acid-ethyl acrylate copolymer (1:1) dispersion 30% (containing sodium lauryl sulphate, polysorbate 80 and methacrylic acid-ethyl acrylate copolymer) Triethyl citrate 20% emulsion of glycerol monostearate, triethyl citrate and polysorbate 80</p><p><u>Capsule shell: </u></p><p>Carrageenan</p><p>Potassium Chloride</p><p>Red Iron Oxide (E-172)</p><p>Titanium Dioxide (E-171)</p><p>Hypromellose Printing Ink (containing Shellac, Potassium hydroxide and Black iron oxide (E172))</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30 &deg;C. Store in the original package in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>EZORA 20 mgis available in:</p><p>Aluminium/Aluminium blisters:</p><p>14 and 28</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p><p>Administration through gastric tube</p><p>1. Put the capsule into an appropriate syringe and fill the syringe with approximately 25 ml water and approximately 5 ml air. For some tubes, dispersion in 50 ml water is needed to prevent the pellets from clogging the tube.</p><p>2. Immediately shake the syringe for approximately 2 minutes to disperse the capsule.</p><p>3. Hold the syringe with the tip up and check that the tip has not clogged.</p><p>4. Attach the syringe to the tube whilst maintaining the above position.</p><p>5. Shake the syringe and position it with the tip pointing down. Immediately inject 5&ndash;10 ml into the tube. Invert the syringe after injection and shake (the syringe must be held with the tip pointing up to avoid clogging of the tip).</p><p>6. Turn the syringe with the tip down and immediately inject another 5&ndash;10 ml into the tube. Repeat this procedure until the syringe is empty.</p><p>7. Fill the syringe with 25 ml of water and 5 ml of air and repeat step 5 if necessary to wash down any sediment left in the syringe. For some tubes, 50 ml water is needed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Towa Pharmaceutical Europe S.L.
C/ de Sant Martí, 75-97,
Martorelles, 08107 Barcelona, Spain
For:
SPIMACO
Al-Qassim pharmaceutical plant
Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                February 2020.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>